Compounding & Access

The OPTN canonical reference on compounding pharmacies and medication access. Living document. Last meaningful expansion: 2026-04-07.

What compounding is

A compounding pharmacy prepares medications for individual patients on a per-prescription basis. Instead of buying mass-manufactured drugs, the pharmacy starts with the active pharmaceutical ingredient (API) and formulates it into the dose, concentration, and delivery method the patient needs.

Compounding lets the medication system flex to meet patient needs the mass-manufacturing system cannot. Custom doses, alternative delivery methods, combinations of medications, formulations for patients with allergies to commercial product fillers, and access to molecules that no pharmaceutical company has chosen to commercialize.

For men’s health, compounding is the reason testosterone costs $40 a month instead of $400, the reason peptide therapy exists outside of clinical trials, and the reason TRT is accessible to patients without expensive insurance coverage.

503A vs. 503B

There are two flavors of compounding pharmacy under federal law, and the distinction matters.

503A pharmacies

Compound for specific patients with specific prescriptions. Regulated primarily by state pharmacy boards, with FDA oversight for limited federal-level rules. Cannot mass-produce or distribute without prescriptions. Most TRT and peptide compounding for individual patients flows through 503A pharmacies.

Examples: Empower Pharmacy, Olympia Pharmacy, Strive Pharmacy, Hallandale Pharmacy.

503B outsourcing facilities

Compound at larger scale and ship to physician offices, clinics, and hospitals. Regulated more like pharmaceutical manufacturers, with full FDA oversight. Can produce in larger batches without patient-specific prescriptions, but cannot fill individual retail prescriptions in the way a 503A can.

Examples: QuVa Pharma, US Compounding, Asclemed.

When men’s health patients talk about “compounding access,” they are almost always talking about 503A. The 503B side is more relevant for hospital and clinic supply chains.

Why this is the linchpin of affordable men’s health

The cost structure of a compounded medication looks nothing like the cost structure of a brand-name pharmaceutical. The active pharmaceutical ingredient is cheap (testosterone cypionate is one of the oldest drugs in the world). The carrier oil is cheap. The vial is cheap. The labor to compound, test, label, and ship is real but modest.

A 503A pharmacy can produce a 10mL vial of 200mg/mL testosterone cypionate for under $30, often closer to $15. The patient pays $40 to $80 because the pharmacy adds a reasonable margin and the prescribing provider takes a fee.

The brand-name version of the same molecule costs $300 to $500 a month. The difference is not the drug. The drug is identical. The difference is the brand-name product is sold by a pharmaceutical company that has spent billions on clinical trials, marketing, and patent protection, and is recouping all of that on each prescription.

Compounding works as a structural cost discipline on the pharmaceutical industry. As long as a 503A pharmacy can legally produce the same active ingredient at a fraction of the cost, the brand-name version cannot sustainably charge premium prices to patients paying out of pocket.

Why pharma fights compounding

Compounding is a structural threat to the pharmaceutical pricing model. Pharma fights it through several channels:

• FDA petitions. Brand-name companies routinely petition the FDA to add specific compounded drugs to the Difficult to Compound list, which restricts 503A pharmacies from making them.
• State legislation. Lobbying state legislatures to add restrictions on what compounding pharmacies can produce.
• Litigation. Lawsuits against compounding pharmacies that produce versions of patented or recently patented products.
• Safety messaging. Funding and amplifying research that emphasizes safety risks of compounding (some legitimate, some exaggerated).
• Insurance pressure. Working with insurers to refuse coverage for compounded versions of brand-name drugs.

Some safety concerns are legitimate. Compounding pharmacies vary in quality, and there have been real cases of contaminated compounds causing patient harm. The 2012 New England Compounding Center fungal meningitis outbreak (which killed 64 people) was a turning point in how the FDA approaches 503B oversight. Quality control matters. PCAB accreditation matters.

But the broader pattern of pharma fighting compounding is not about safety. It is about pricing.

The 2023-2026 peptide story

A timeline of how peptide compounding access evolved over the past three years.

Late 2023: The FDA places 14 commonly compounded peptides on the Difficult to Compound list. The cited reasons include safety, characterization, and the lack of pharmaceutical-grade reference standards for some peptides. The peptides included BPC-157, TB-500, CJC-1295, Ipamorelin, Sermorelin, and others. Compounding pharmacies that had been formulating these legally for years suddenly faced enforcement risk if they continued.

2024: Patient access for these peptides through legal channels effectively dries up. Some compounders continue to formulate them in defiance of the new rules, accepting the risk. Others switch to gray-market or international supply chains. A few peptides remain available because they fall outside the restricted list. Patient advocacy groups, compounding pharmacy associations (Alliance for Pharmacy Compounding), and individual physicians push back.

2025: Brand-name semaglutide pricing remains sky-high. Compounded semaglutide (which had been a major access pathway for patients without insurance coverage) becomes legally murky and varies by pharmacy and state.

February 2026: HHS reverses parts of the 2023 decision. Fourteen peptides are reclassified back to legal compounding status under specific conditions. The reversal is framed as a patient access issue and is supported by both pharmacy advocacy and physician groups.

Where we are now: Compounding access for the reclassified peptides has been restored. The longer-term regulatory direction is unclear and the fight will continue. Patients should know which side of the fight their access depends on.

OPTN reports this factually. It is not framed as a political story.

How to evaluate a compounding pharmacy

If you are going to use a compounding pharmacy, the things worth asking about:

• PCAB accreditation. The Pharmacy Compounding Accreditation Board is the gold standard. PCAB-accredited pharmacies undergo regular third-party audits.
• API source. Where does the active pharmaceutical ingredient come from? USP grade is the standard. Reputable suppliers include Letco, Medisca, and PCCA.
• Sterility testing. For injectable preparations, the pharmacy should test for sterility. Larger 503A operations test in-house. Smaller ones contract this out.
• Endotoxin testing. Especially for injectables.
• Beyond-use date practices. How long can a vial sit on the shelf and still be considered safe? PCAB accreditation enforces standards here.
• Recalls and complaints. Search the FDA recall database and state pharmacy board records.

The big national 503A pharmacies that ship to most states (Empower, Olympia, Strive, Hallandale) are generally well-regarded for quality. Local 503A pharmacies vary more.

States with friction

Compounding access is federal at the FDA level but heavily mediated by state pharmacy boards. Some states make access easier; some make it harder.

A few examples of state-level friction:

• Texas: Generally permissive for compounded testosterone access.
• California: More restrictive than most. Requires more documentation for some compounded products.
• New York: Tightly regulated. Some popular compounded products are not available to NY residents.
• Maine: Notably permissive for testosterone access. Testosterone is exempt from the state controlled substance monitoring program under LD 1277, which removes a layer of friction that exists in most other states.

Sources and further reading

• FDA Drug Compounding and Compounding Quality Act (2013) reference page
• Alliance for Pharmacy Compounding (a4pc.org)
• HHS announcement on peptide reclassification (Feb 2026, primary source)
• PCAB Accreditation Standards (current edition)

This wiki will continue to grow as the regulatory environment shifts.